We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in the Offing for Exelon (EXC) This Earnings Season?
Read MoreHide Full Article
We expect Exelon Corporation (EXC - Free Report) to beat earnings estimates when it reports third-quarter 2019 results on Oct 31, 2019. The company came up with a negative earnings surprise of 4.76% in the last reported quarter.
What Our Quantitative Model Predicts
Our proven model predicts an earnings beat for Exelon this time around. A stock needs to have both a positive Earnings ESP (which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate) and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to surpass estimates. That is the case here as you will see below.
Earnings ESP: The company’s Earnings ESP is +0.06%.
You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Currently, Exelon carries a Zacks Rank #3.
Higher demand for electricity in July due to extreme heat in its service territories and solid production from nuclear plants are likely to have had a positive impact on third-quarter earnings.
The shutdown of the Three Mile Island nuclear plant during the quarter might have saved the company from incurring high costs on this non-profitable unit and boosted margins.
Exelon expects third-quarter earnings in the range of 80-90 cents per share. The bottom line was 88 cents in the year-ago period. The Zacks Consensus Estimate for the same is pegged at 88 cents, indicating no change from the year-ago reported figure.
Stocks to Consider
In addition to Exelon, here are a few other companies worth considering from the same industry that have the right combination of elements to beat on earnings in the third quarter.
Pattern Energy Group Inc. is set to release quarterly numbers on Nov 4. It has an Earnings ESP of +2,100.00% and carries a Zacks Rank #2.
Eversource Energy (ES - Free Report) is slated to release quarterly results on Nov 5. It has an Earnings ESP of +1.06% and a Zacks Rank #2.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
What's in the Offing for Exelon (EXC) This Earnings Season?
We expect Exelon Corporation (EXC - Free Report) to beat earnings estimates when it reports third-quarter 2019 results on Oct 31, 2019. The company came up with a negative earnings surprise of 4.76% in the last reported quarter.
What Our Quantitative Model Predicts
Our proven model predicts an earnings beat for Exelon this time around. A stock needs to have both a positive Earnings ESP (which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate) and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to surpass estimates. That is the case here as you will see below.
Earnings ESP: The company’s Earnings ESP is +0.06%.
You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Currently, Exelon carries a Zacks Rank #3.
Exelon Corporation Price and EPS Surprise
Exelon Corporation price-eps-surprise | Exelon Corporation Quote
Factors at Play
Higher demand for electricity in July due to extreme heat in its service territories and solid production from nuclear plants are likely to have had a positive impact on third-quarter earnings.
The shutdown of the Three Mile Island nuclear plant during the quarter might have saved the company from incurring high costs on this non-profitable unit and boosted margins.
Exelon expects third-quarter earnings in the range of 80-90 cents per share. The bottom line was 88 cents in the year-ago period. The Zacks Consensus Estimate for the same is pegged at 88 cents, indicating no change from the year-ago reported figure.
Stocks to Consider
In addition to Exelon, here are a few other companies worth considering from the same industry that have the right combination of elements to beat on earnings in the third quarter.
PNM Resources Inc. (PNM - Free Report) is scheduled to release quarterly results on Nov 1. It has an Earnings ESP of +1.99% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Pattern Energy Group Inc. is set to release quarterly numbers on Nov 4. It has an Earnings ESP of +2,100.00% and carries a Zacks Rank #2.
Eversource Energy (ES - Free Report) is slated to release quarterly results on Nov 5. It has an Earnings ESP of +1.06% and a Zacks Rank #2.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>